Table 2 Physiological responses to ABR-214936 treatment

From: A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma

 

Anti-SEA (pmol ml−1)

HAMA (pmol ml−1)

IL-2 (pg ml−1)

Visit

n

Median

Range

n

Median

Range

Mean±s.d.

Median

Range

Baseline

43

87.0

15–6400

43

0

0–0

   

Day 1

43

     

37.8±70

9.2

0–357.7

Day 2

43

     

6.7±13.3

4

0–87.2

Day 28

40

46 700

79–445 000

41

0.058

0–9.36

   

Day 56

38

31 600

113–241 000

      

Day 112

27

25 100

175–176 000

26

1.542

0–16.4

   
  1. Anti-SEA and HAMA titres measured at baseline and after each cycle of treatment and circulating IL-2 measured on days 1 and 2 of cycle 1.
Back to article page